For immediate release

Lumora Develops RapidMag, a New Sample Preparation Tool

Cambridgeshire, UK, 17 May 2014 ... Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial market, has developed RapidMag, a new sample preparation tool for whole blood and plasma which can be used with PCR, Isothermal amplification systems and NGS.

RapidMag, which was unveiled today at the American Society for Microbiology conference in Boston, has a number of advantages over existing sample preparation technologies, and through its unique design, it is able to greatly reduce the number of steps required to process concentrated DNA and RNA samples. Sample preparation using RapidMag takes just three steps and can be completed in just 20 minutes, compared to more 40 minutes for some existing sample preparation processes. 

Lawrence Tisi, CEO of Lumora, said: “Sample preparation is a key part of all testing, and can significantly add to the time required. By using RapidMag, laboratories can significantly reduce the amount of time required in sample preparation, saving not only time, but also a significant cost.  

Hayden Jeffreys, Commercial Director at Lumora, added: “The development of RapidMag further strengthens Lumora’s position in the development of novel sample preparation technologies. When combined with our diagnostic products, sample preparation technologies such as RapidMag give Lumora a strong commercial position.”

-ends-

For further information please contact:

Tony Stephenson, Director

Exitus Communications 

Tel: +44 (0)7899 796655

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.  

Notes to Editors: 

About Lumora

Lumora is a successful provider of state-of-the-art molecular diagnostic products into both the clinical and non clinical or industrial markets. Lumora's easy to deploy and use technology can be employed in fields as diverse as food safety testing, and medical diagnostics. The Company is active in licensing its technology and development partners include international biotechnology, clinical diagnostic and industrial microbiology companies.

Lumora's corporate office is based just outside of Cambridge, England. The Company's investors include; Tate Lyle Ventures LP, Cambridge Enterprise (University of Cambridge), and Catapult Venture Managers Ltd.
www.lumora.co.uk